Publications

BibTex format

@article{Wilson:2016:10.1080/00498254.2016.1206239,
author = {Wilson, ID},
doi = {10.1080/00498254.2016.1206239},
journal = {Xenobiotica},
pages = {538--546},
title = {Lumiracoxib metabolism in male C57bl/6J mice: characterisation of novel in vivo metabolites},
url = {http://dx.doi.org/10.1080/00498254.2016.1206239},
volume = {47},
year = {2016}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - 1. The pharmacokinetics and metabolism of lumiracoxib in male C57bl/6J mice were investigated following a single oral dose of 10 mg/kg.2. Lumiracoxib achieved peak observed concentrations in the blood of 1.26 + 0.51 μg/mL 0.5 h (0.5–1.0) post-dose with an AUCinf of 3.48 + 1.09 μg h/mL. Concentrations of lumiracoxib then declined with a terminal half-life of 1.54 + 0.31 h.3. Metabolic profiling showed only the presence of unchanged lumiracoxib in blood by 24 h, while urine, bile and faecal extracts contained, in addition to the unchanged parent drug, large amounts of hydroxylated and conjugated metabolites.4. No evidence was obtained in the mouse for the production of the downstream products of glutathione conjugation such as mercapturates, suggesting that the metabolism of the drug via quinone–imine generating pathways is not a major route of biotransformation in this species. Acyl glucuronidation appeared absent or a very minor route.5. While there was significant overlap with reported human metabolites, a number of unique mouse metabolites were detected, particularly taurine conjugates of lumiracoxib and its oxidative metabolites.
AU  - Wilson,ID
DO  - 10.1080/00498254.2016.1206239
EP  - 546
PY  - 2016///
SN  - 1366-5928
SP  - 538
TI  - Lumiracoxib metabolism in male C57bl/6J mice: characterisation of novel in vivo metabolites
T2  - Xenobiotica
UR  - http://dx.doi.org/10.1080/00498254.2016.1206239
UR  - http://hdl.handle.net/10044/1/38398
VL  - 47
ER  -

Download

ProfessorIanWilson

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)